Companies

Elastrin Therapeutics is a US and UK-based biotech startup developing novel therapies to reverse chronic cardiovascular and lung diseases. Its underlying technology was developed by Prof. Vyavahare during the last 20 years at Clemson University. The team consists of seven experts and has built a proprietary platform that can restore vascular health by removing pathological calcification and restoring elastin damage. This is achieved by targeting drug-loaded nanoparticles directly to the diseased tissue where elastin has been degraded using the company’s proprietary antibody. Elastrin’s lead product will be tested in clinical trials starting in 2024 and become commercially available in 2027.

Recently, here at Elastrin Therapeutics, we have moved lab spaces to double our R&D production. We now have increased our capabilities to add additional groundbreaking technologies. These technologies will allow us to more efficiently produce a product that can quickly be scaled-up and brought to a clinical trial. This new lab space and equipment will support our vision of reversing tissue and organ calcification, which will, in turn, save billions of lives.

Elastrin Therapeutics

Samaritan Biologics is a regenerative medicine company based in Memphis, Tennessee, with the tagline: Helping, Healing, Giving. Samaritan Biologics is partnered with AATB-accredited tissue banks and medical device companies to develop future healing solutions that include perinatal tissue grafts, cadaveric allografts, and biomaterial grafts.

Samaritan Biologics recently obtained wet lab space at CUBEInC, enabling Samaritan to continue to develop and evaluate next-generation, best-in-class human allografts, biomaterials and biologic products in collaboration with world-class clinicians and scientists.

Samaritan Biologics

Annoviant is a healthcare innovation company dedicated to developing medical devices that transform and save lives worldwide. Annoviant is currently exploring cardiovascular applications of a breakthrough technology that improves soft tissue healing.

Implementation and application of innovative technologies require an ecosystem where there are trustworthy actions and nurturing relationships. Our focus is to build confidence by collaborating with our customers to identify and address unmet needs to reduce the emotional and economic burden of the people we serve. Actively engaging with our customers (patients, surgeons, and healthcare networks) is essential in identifying gaps in the healthcare needs of the communities we serve. Addressing the customer's needs is at the core of everything we do.

Annoviant

NeuroHope Therapeutics, Inc. is a start-up company pursuing the development and commercialization of a proprietary polymer-based drug delivery system invented by Jeoung Soo Lee at Clemson University. Through a combination of material design and delivery route, their technology can provide targeted delivery of different types of pharmaceuticals, alone or in combination. This approach allows them to achieve therapeutic doses in local tissues, while minimizing systemic side effects. In addition, NeuroHope’s delivery carrier is a platform technology that can be applied to a wide range of drugs and disease conditions. The first product is intended to treat acute spinal cord injury, providing patients with improved recovery of motor and sensory function.

NeuroHope Therapeutics